AIM: To determine the frequency and pattern of @entity4461 in @entity1 with @entity1582 ( @entity1582 ) and to evaluate the adequacy of preventive anticoagulant or antiaggregant therapy. SUBJECTS AND METHODS: The prospective study conducted at the Department for High-Dose Chemotherapy and Bone Marrow Transplantation, Hematology Research Center, Ministry of Health of the Russian Federation, in March 2012 to May 2013, enrolled 25 @entity1 (13 @entity1 and 12 @entity1 ) aged 29-72 years (median age 54 years) with new-onset @entity1582 . The latter was staged using the Durie-Salmon classification: Stages I, II, and III were determined in 2, 10, and 13 @entity1 , respectively. Seven @entity1 were found to have @entity8 (which corresponded to Substage B). The hemostasis was evaluated from the results of the following tests: activated partial thromboplastin time (APTT), @entity556 time (TT), Xlla-dependent fibrinolysis time, Quick prothrombin index, international normalized ratio (INR), and @entity2002 and D-dimer concentrations. The investigators used new hemostatic techniques, such as @entity556 generation test, thromboelastography, as well as thrombodynamics, a novel method to determine the characteristics of spatial clot growth. Induction therapy was performed using the PAD and VCD regimens. @entity715 were prevented by using 24-hour infusion of unfractionated heparin (500 U/hr) or by administering @entity117 (100 mg/day). RESULTS: @entity49 was identified in 17 (68%) @entity1 . Eleven (44%) @entity1 had elevated D-dimer concentrations. The level of D-dimer was statistically significantly positively correlated with the endogenous @entity556 potential and the amount of @entity2262 . The thrombodynamic technique revealed an inverse relationship between the level of paraprotein and the optimal density of a fibrin clot. A @entity715 episode was seen in one elderly (71-year-old) @entity1 after @entity117 discontinuation during long-term immobilization. CONCLUSION: Nearly 50% of the primary @entity1 with @entity1582 were ascertained to be more prone to @entity715 . Infusion of unfractionated heparin in a dose of 500 U/hr or administration of @entity117 (100 mg/day) was the adequate prevention of @entity715 events.

[ XXXX in @entity1582 ].

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'men'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal dysfunction'] @entity2002 :: ('2244', 'Gene') :: ['fibrinogen'] @entity556 :: ('2147', 'Gene') :: ['thrombin'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity2262 :: ('567', 'Gene') :: ['beta2-microglobulin'] @entity49 :: ('MESH:D019851', 'Disease') :: ['Hypercoagulability'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma', 'MM'] @entity4461 :: ('MESH:D020141', 'Disease') :: ['blood clotting disorders'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis', 'thrombotic', 'Thromboses']
@entity49 :: (MESH:D019851,Disease) :: ['Hypercoagulation syndrome']
